In the realm of head and neck cancer, organoid models have played a crucial role in revealing the synergistic effects of targeting thioredoxin reductase 1 (TrxR1) inhibition in conjunction with anti-PD-1 therapy, thereby emphasizing the potential of ferroptosis induction to enhance therapeutic outcomes in cancer treatment [77]. Here, TXNRD1 is linked to cancer.